BEDMINSTER, N.J., June  26, 2026  (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the &#34;Company&#34;) (NYSE:MTNB) announced today that on June 24, 2026, it received a notice (the &#34;Notice&#34;) from the NYSE

MTNB

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance

Matinas BioPharma gets NYSE plan to regain listing by Oct 2027

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>BEDMINSTER, N.J., June  26, 2026  (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the &amp;#34;Company&amp;#34;) (NYSE:MTNB) announced today that on June 24, 2026, it received a notice (the &amp;#34;Notice&amp;#34;) from the NYSE</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Matinas BioPharma received a Notice of Non-Compliance from NYSE American regarding stockholders’ equity below required thresholds. The exchange accepted a remediation plan that extends through October 2, 2027, with quarterly compliance reviews, and there is no immediate impact on listing or operations. MAT2203 remains a potential upside driver, but the primary near-term focus is achieving compliance to preserve listed status.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>NYSE American cites MTNB equity below thresholds. Plan to regain by Oct 2, 2027.</li><li>Equity at 3/31/2026: MTNB $3.02M, below minimums under Company Guide.</li><li>Plan accepted by NYSE; MTNB may remain listed through Plan Period with quarterly reviews.</li><li>No immediate listing impact; MTNB operations and SEC reporting unaffected.</li><li>MAT2203 phase 2 EnACT showed robust survival in cryptococcal meningitis.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Matinas BioPharma Holdings, Inc. (MTNB)</strong>: Subject of the listing non-compliance; plan to regain compliance by 2027; no immediate operational impact.</li><li><strong>NYSE American LLC (NYSE American)</strong>: Regulator issuing the notice and overseeing plan-based remediation through 2027.</li><li><strong>AmBisome (liposomal amphotericin B) (N/A)</strong>: Referenced as standard of care; MAT2203 aims to offer oral delivery with potentially better safety.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. Regulatory/compliance update; impacts MTNB&#039;s listing status and access to capital if progress stalls.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Plan acceptance preserves MTNB listing through 2027, reducing near-term delisting risk.</li><li>Equity shortfall remains $3.02M as of 3/31/2026, below the $4M threshold.</li><li>Ongoing quarterly monitoring creates regulatory overhang and visibility into progress.</li><li>MAT2203 clinical prospects offer optionality but no near-term revenue guidance.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>MTNB equity 3/31/2026: $3.02 million; below the $4.0 million threshold for 1003(a)(ii).</li><li>As of 12/31/2025, MTNB had $4.83 million in stockholders’ equity and five straight years of losses.</li><li>Plan submitted May 4, 2026; NYSE American granted plan period through Oct 2, 2027.</li><li>Notice states delisting possible if progress fails; MTNB may appeal under Company Guide.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Neutral near-term; a successful compliance restoration by 2027 could unlock upside.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">BEDMINSTER, N.J., June  26, 2026  (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/MTNB">MTNB</a>) announced today that on June 24, 2026, it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the "Company Guide") requiring a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company had stockholders’ equity of $3.02 million and has had losses in the most recent five fiscal years ended December 31, 2025. As previously disclosed, the Company is also not in compliance with Section 1003(a)(iii) of the Company Guide requiring a company to have stockholders’ equity of at least $6.0 million if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years. As of December 31, 2025, the Company had stockholders’ equity of $4.83 million and has had losses in the most recent five fiscal years ended December 31, 2025. Due to its non-compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the Company Guide, the Company is subject to the procedures and requirements of Section 1009 of the Company Guide.</p>  <p align="justify">On May 4, 2026, the Company submitted a plan (the "Plan") to the NYSE American advising of actions it has taken or will take to regain compliance with the continued listing standards. The Notice indicated that the NYSE American staff had determined to accept the Plan and grant the Company a plan period through October 2, 2027 (the "Plan Period," and such date, the "Plan Period Deadline"). Accordingly, the Company is able to continue its listing during the Plan Period and will be subject to periodic reviews, including quarterly monitoring, for compliance with the Plan until it has regained compliance. However, there can be no assurance that the Company will be able to achieve compliance with such standards within the Plan Period. If the Company is not in compliance with the continued listing standards by the Plan Period Deadline, or if the Company does not make progress consistent with the Plan during the Plan Period, then NYSE American staff may initiate delisting proceedings as appropriate. The Company may appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide.</p>  <p align="justify">The Notice has no immediate impact on the listing of the Company’s shares of common stock, which will continue to be listed and traded on the NYSE American, subject to the Company’s compliance with the other listing requirements of the NYSE American. The Notice does not affect the Company’s ongoing business operations or its reporting requirements with the Securities and Exchange Commission.<br></br>  <br></br><strong>About Matinas BioPharma</strong></p>  <p align="justify">Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology.</p>  <p align="justify"><strong>About MAT2203</strong></p>  <p align="justify">Matinas BioPharma’s MAT2203 is a potential oral broad-spectrum treatment for invasive deadly fungal infections. Although amphotericin B is a fungicidal agent, it is currently only available through an intravenous route of administration, which is known to be associated with several significant safety issues such as renal toxicity and anemia due to very high circulating levels of amphotericin B. MAT2203 has the potential to overcome the significant limitations of the currently available amphotericin B products due to its targeted oral delivery. Combining comparable fungicidal activity with targeted delivery results in a lower risk of toxicity and potentially creates the ideal antifungal agent for the treatment of invasive fungal infections. MAT2203 was successfully evaluated in the completed Phase 2 EnACT study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 was planned to be further evaluated in a single Phase 3 registration trial as an oral step-down monotherapy following treatment with AmBisome (liposomal amphotericin B) compared with the standard of care in patients with invasive aspergillosis who have limited treatment options.</p>  <p align="justify">For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=f1uVW6AUqxLfnrDdzMeBHRiM0LxFm9OqhQuWSqyiCJB0ih3xUa_wDUK1HzPGP3X9qAouSqjlcVlZn5uBGIfQ_wNSW-LFMe8EkETbiDjp-7PePt4E54V2gYI8uOnM82aW" rel="nofollow" target="_blank">www.matinasbiopharma.com</a>. </p>  <p align="justify"><strong>Forward-Looking Statements </strong></p>  <p align="justify">This release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this release are forward-looking statements. Forward-looking statements contained in this release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "suggest," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including with respect to the Company’s plans related to regaining compliance with the NYSE American’s continued listing standards. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the risk disclosures in the Annual Report on Form 10-K of the Company for the year ended December 31, 2025 and in other filings made with the Securities and Exchange Commission by the Company. All such forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc1MzAzNSM3Njc5NjA0IzIwMjM2MTg="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NzM4MWIxZWUtNzY2Ni00MDc4LWE0OTItYWE2NGQ2ZmY0YWFiLTEwMzUxODYtMjAyNi0wNi0yNi1lbg==/tiny/Matinas-BioPharma-Holdings-Inc.png" referrerpolicy="no-referrer-when-downgrade"></img><pre>Investor Contact

Jerome D. Jabbour
Chief Executive Officer
(908) 484-8805
operations@matinasbiopharma.com</pre><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/3e39a977-df68-4f07-8991-d85b43720347"><img src="https://ml.globenewswire.com/media/3e39a977-df68-4f07-8991-d85b43720347/small/matinas-biopharma.jpg" border="0" width="150" height="58" alt="Primary Logo"></img></a></p>

Matinas BioPharma received a Notice of Non-Compliance from NYSE American regarding stockholders’ equity below required thresholds. The exchange accepted a remediation plan that extends through October 2, 2027, with quarterly compliance reviews, and there is no immediate impact on listing or operations. MAT2203 remains a potential upside driver, but the primary near-term focus is achieving compliance to preserve listed status.

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News